* Witty on first visit to China since bribery scandal
* CEO expects update on graft investigation "quite soon"
* GSK spokesman says trade trip shows commitment to China
LONDON/BEIJING, Dec 2 (Reuters) - GlaxoSmithKline's (GSK) chief executive is showing his commitment to doingbusiness in China by joining a trade trip there, a GSK spokesmansaid on Monday, after allegations of illegal payments to Chinesedoctors and officials.
Andrew Witty declined to comment on the investigation intoalleged corruption but he told Reuters in Beijing that theBritish drugmaker would have something to say "quite soon".
Witty - on his first visit to the country since thecorruption scandal blew up in July - is in China as part of a100-strong business delegation with British Prime Minister DavidCameron.
"It's an important opportunity to show our continuedcommitment to China and to supplying our medicines to thecountry," GSK spokesman Simon Steel said in London.
Chinese police have accused GSK of funnelling up to 3billion yuan ($492 million) to travel agencies to facilitatebribes to boost its drug sales. The accusations are the mostserious against a multinational in China in years.
GSK's sales in China dived 61 percent in the third quarterafter hospital staff shunned visits by its sales teams in thewake of the investigation.
Legal and industry sources told Reuters last month thatpolice were likely to charge some of GSK's Chinese executivesbut not the company itself. One person with direct knowledge ofthe situation said the police investigation was likely to beconcluded by around early December.
GSK has said some of its senior Chinese executives appear tohave broken the law. It has also said it has zero tolerance forbribery, calling the allegations in China "shameful".
GSK sold 759 million pounds ($1.2 billion) ofpharmaceuticals and vaccines in China in 2012, up 17 percent on2011, representing about 3.5 percent of its worldwide total.